Aytu Biopharma (AYTU) Common Equity: 2011-2025
Historic Common Equity for Aytu Biopharma (AYTU) over the last 13 years, with Sep 2025 value amounting to $23.2 million.
- Aytu Biopharma's Common Equity fell 22.31% to $23.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $23.2 million, marking a year-over-year decrease of 22.31%. This contributed to the annual value of $19.0 million for FY2025, which is 31.57% down from last year.
- Aytu Biopharma's Common Equity amounted to $23.2 million in Q3 2025, which was up 22.17% from $19.0 million recorded in Q2 2025.
- In the past 5 years, Aytu Biopharma's Common Equity ranged from a high of $143.2 million in Q1 2021 and a low of $19.0 million during Q2 2025.
- Its 3-year average for Common Equity is $31.0 million, with a median of $30.8 million in 2024.
- Per our database at Business Quant, Aytu Biopharma's Common Equity skyrocketed by 44.79% in 2021 and then crashed by 67.79% in 2022.
- Quarterly analysis of 5 years shows Aytu Biopharma's Common Equity stood at $105.5 million in 2021, then tumbled by 56.59% to $45.8 million in 2022, then dropped by 28.30% to $32.9 million in 2023, then declined by 6.36% to $30.8 million in 2024, then dropped by 22.31% to $23.2 million in 2025.
- Its Common Equity stands at $23.2 million for Q3 2025, versus $19.0 million for Q2 2025 and $34.9 million for Q1 2025.